Cardiff Oncology Toekomstige groei

Future criteriumcontroles 0/6

De omzet en winst van Cardiff Oncology zullen naar verwachting dalen met respectievelijk 34.8% en 27.9% per jaar, terwijl de winst per aandeel naar verwachting zal dalen met 18.3% per jaar.

Belangrijke informatie

-27.9%

Groei van de winst

-18.3%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	-34.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 Nov 2024

Recente toekomstige groei-updates

Recent updates

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Nov 07

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 01

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Feb 22

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Sep 14

Cardiff Oncology: Down But Not Out

Aug 22

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Jun 20

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Jun 07

Cardiff Oncology: Risky Investment

May 19

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Mar 01

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Jan 28

Cardiff: The Pfizer Interest Is Interesting

Dec 15

Circling Back On Cardiff Oncology

Oct 12

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Aug 26

Cardiff Oncology: Current Slump Doesn't Look Right

Jun 14

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Apr 29

How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Feb 28

What Type Of Shareholders Own The Most Number of Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?

Jan 24

Winst- en omzetgroeiprognoses

NasdaqCM:CRDF - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	0	-71	-62	-67	4
12/31/2025	0	-55	-49	-48	5
12/31/2024	1	-46	-43	-38	5
9/30/2024	1	-43	-35	-35	N/A
6/30/2024	1	-41	-32	-32	N/A
3/31/2024	1	-40	-31	-30	N/A
12/31/2023	0	-41	-31	-31	N/A
9/30/2023	0	-41	-34	-33	N/A
6/30/2023	0	-40	-33	-33	N/A
3/31/2023	0	-39	-33	-32	N/A
12/31/2022	0	-39	-35	-34	N/A
9/30/2022	0	-39	-33	-32	N/A
6/30/2022	0	-38	-30	-30	N/A
3/31/2022	0	-34	-28	-27	N/A
12/31/2021	0	-28	-23	-23	N/A
9/30/2021	0	-25	-21	-21	N/A
6/30/2021	0	-23	-19	-19	N/A
3/31/2021	0	-24	-19	-19	N/A
12/31/2020	0	-23	-17	-16	N/A
9/30/2020	0	-20	-15	-14	N/A
6/30/2020	0	-20	-14	-14	N/A
3/31/2020	0	-17	-13	-13	N/A
12/31/2019	0	-17	-13	-13	N/A
9/30/2019	0	-17	-14	-14	N/A
6/30/2019	0	-16	-14	-14	N/A
3/31/2019	0	-19	-14	-14	N/A
12/31/2018	0	-19	-13	-13	N/A
9/30/2018	0	-18	-13	-13	N/A
6/30/2018	1	-18	N/A	-16	N/A
3/31/2018	1	-20	N/A	-17	N/A
12/31/2017	1	-25	N/A	-23	N/A
9/30/2017	0	-31	N/A	-29	N/A
6/30/2017	0	-37	N/A	-29	N/A
3/31/2017	0	-39	N/A	-33	N/A
12/31/2016	0	-39	N/A	-31	N/A
9/30/2016	0	-38	N/A	-29	N/A
6/30/2016	0	-31	N/A	-27	N/A
3/31/2016	0	-31	N/A	-24	N/A
12/31/2015	0	-27	N/A	-22	N/A
9/30/2015	0	-25	N/A	-19	N/A
6/30/2015	0	-27	N/A	-17	N/A
3/31/2015	0	-18	N/A	-15	N/A
12/31/2014	0	-14	N/A	-13	N/A
9/30/2014	0	-11	N/A	-11	N/A
6/30/2014	0	-10	N/A	-9	N/A
3/31/2014	0	-14	N/A	-8	N/A
12/31/2013	0	-12	N/A	-7	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CRDF de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CRDF de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CRDF de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CRDF zal naar verwachting de komende 3 jaar dalen ( -34.8% per jaar).

Hoge groei-inkomsten: De omzet van CRDF zal naar verwachting de komende 3 jaar dalen ( -34.8% per jaar).

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van CRDF naar verwachting over 3 jaar hoog zal zijn

Cardiff Oncology Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 61%

Consensus EPS estimates upgraded to US$0.97 loss

Price target increased by 13% to US$9.03

Consensus revenue estimates increase by 48%

Price target decreased by 7.8% to US$7.68

Consensus revenue estimates fall by 50%

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cardiff Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Insufficient new directors

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

Consensus revenue estimates increase by 61%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc., Annual General Meeting, Jun 20, 2024

Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Consensus EPS estimates upgraded to US$0.97 loss

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Price target increased by 13% to US$9.03

Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC

Cardiff Oncology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cardiff Oncology, Inc. Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, Including Single-Agent Activity from Onvansertib Monotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 48%

Cardiff Oncology, Inc Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

Price target decreased by 7.8% to US$7.68

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Consensus revenue estimates fall by 50%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 14%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology Appoints Fairooz Kabbinavar as Chief Medical Officer

Price target decreased to US$8.49

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.49

Independent Director recently bought US$257k worth of stock

Price target decreased to US$10.70

Consensus forecasts updated

Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment

Price target decreased to US$12.70

Cardiff Oncology, Inc. Announces Plans for A Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1B/2 Trial in mCRC

Cardiff Oncology: Down But Not Out

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cardiff Oncology, Inc.(NasdaqCM:CRDF) dropped from Russell 2000 Value Index

Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Cardiff Oncology: Upcoming Readouts And Several Green Lights

Cardiff Oncology: Risky Investment

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.00

Cardiff Oncology, Inc., Annual General Meeting, Jun 09, 2022

Cardiff Oncology, Inc. Announces Executive Changes

Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting

Consensus forecasts updated

Consensus forecasts updated

Cardiff: A Long-Term Biotech To Own Based On Overcoming Cancer Resistance

Full year 2021 earnings: EPS and revenues exceed analyst expectations

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Price target decreased to US$21.00

Consensus forecasts updated

Cardiff: The Pfizer Interest Is Interesting

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.19 loss in 3Q 2020)

Circling Back On Cardiff Oncology

Independent Director recently bought US$203k worth of stock